(FDMT) 4D Molecular Therapeutics, Inc. Business Model Canvas Research

The Cystic Fibrosis Foundation (CFF) backs 4D Molecular Therapeutics, Inc.'s 4D-710 cystic fibrosis program, giving it rare disease know-how, patient input, and stronger clinical visibility. For pulmonology, that support matters because CFF-funded CF research has helped move care from symptom control toward disease-modifying therapies, and 4D-710 is being advanced in a Phase 1/2 study.

• Supports 4D-710 development
• Improves patient and trial insight
• Raises pulmonology awareness

Clinical investigators and specialized trial sites are core partners for 4D Molecular Therapeutics, Inc. because its Phase 1/2 programs depend on principal investigators to enroll patients and collect human safety and efficacy data. In 2025, these sites remained central to the company’s clinical-stage work across its gene therapy pipeline, where early human data drives go/no-go decisions.

• Enable patient enrollment
• Generate safety data
• Read out efficacy signals

4D Molecular Therapeutics, Inc. uses target-disease research across 3 focus areas—ophthalmology, cardiology, and pulmonology—to map disease biology, then match it to vector construct design and indication choice. This feeds pipeline prioritization, helping direct capital to the programs with the strongest biological fit.

• 3 core disease areas
• Biology guides construct design
• Biology guides indication selection
• Prioritizes pipeline spend

4D Molecular Therapeutics, Inc. needs GMP-grade vector manufacturing and release testing to keep gene therapy batches usable for clinical supply and regulator review. In gene therapy, each lot must clear identity, potency, sterility, and purity checks, so strong quality systems are what keep trials from stalling when supply is tight.

• GMP vector output supports trial dosing
• Release tests confirm batch quality
• Quality systems protect regulatory compliance

4D Molecular Therapeutics, Inc.'s partner network adds 4 named external links — uniQure, CRF, Roche, and CFF — that extend internal capabilities in research, validation, and development. This matters because 4D can tap outside expertise while keeping its platform lean.

• 4 key partners
• Supports research and validation
• Extends internal resources

4D Molecular Therapeutics, Inc.’s Emeryville, California headquarters anchors administration and R&D coordination, keeping core decisions, lab planning, and program oversight in one place. The Bay Area base also gives the company close access to one of the nation’s deepest life sciences talent pools.

• Supports admin and R&D coordination
• Anchors company operations
• Improves access to Bay Area talent

4D Molecular Therapeutics, Inc. frames gene therapy as a one-time intervention that targets disease at the genetic level, aiming for a long-duration effect instead of recurring dosing. In eye care, this could replace the 6-12 anti-VEGF injections many wet AMD patients get each year, cutting treatment burden if durability holds.

• One treatment, not repeated dosing
• Targets disease at the gene level
• May reduce chronic care burden

4D Molecular Therapeutics, Inc. uses human proof-of-concept to show safety and early efficacy in patients, which can validate its AAV-based platform and lower late-stage risk. Clinical data from its lead programs can turn lab science into investor proof, especially as the Company advances multiple programs across eye, heart, and lung disease.

• Shows patient safety and response
• Validates the delivery platform
• De-risks later trials and funding

Regulatory and medical affairs communication at 4D Molecular Therapeutics, Inc. is formal and process-led: every IND and clinical trial update needs steady regulator contact, clean safety reporting, and tight data packages to keep studies moving. This matters because even one late adverse-event report can stall development, so the relationship is built on speed, accuracy, and traceable records.

• Formal IND and trial updates
• Clear safety and data reporting
• Continuous regulator contact

4D Molecular Therapeutics uses a partner-led collaboration model, where R&D ties are structured around shared development goals and milestone triggers. This keeps customer relationships science-heavy and tied to data, not sales volume.

• Milestone-based R&D partnerships
• Shared development objectives
• Data-driven, long-cycle collaboration

4D Molecular Therapeutics, Inc. uses scientific and medical conferences to present trial data, meet investigators and partners, and reach investors in one setting. These forums matter for credibility and for faster data diffusion across the eye and gene therapy field.

• Share clinical data fast
• Build trust with experts
• Reach partners and investors

4D Molecular Therapeutics, Inc. uses its corporate website and investor materials to post SEC filings, pipeline updates, and trial milestones, so shareholders, analysts, and potential partners can track progress in real time. As a pre-commercial Company, 2025 product revenue was $0, which makes clear disclosure the main way it builds trust.

• Pipeline status is shared through filings.
• Reaches shareholders, analysts, partners.
• Supports transparency before commercialization.

Patients with cystic fibrosis lung disease are the core segment for 4D Molecular Therapeutics, Inc.'s 4D-710, a chronic respiratory gene therapy built for inhaled, airway-focused delivery. Cystic fibrosis affects about 105,000 people worldwide and roughly 40,000 in the United States, and many still lack effective lung-targeted treatment options.

• High unmet need in lung delivery
• Requires inhaled airway therapy
• Large, chronic rare-disease market

Hospitals, research centers, and specialists are 4D Molecular Therapeutics, Inc.’s first clinical users: they recruit patients, run trials, and guide treatment choices before any broad launch. In a clinical-stage model, these sites act as the gatekeepers between lab data and real-world adoption, and they shape safety and efficacy readouts that drive later licensing and commercialization.

• Trial enrollment and protocol execution
• Diagnosis and patient selection
• Treatment guidance and follow-up

External research partnership costs rise because 4D Molecular Therapeutics works with 4 named partners: uniQure, CRF, Roche, and the Cystic Fibrosis Foundation. These deals can include sponsored research and service fees, so outside capabilities add to the 2025 cost base even when partner-level spend is not separately disclosed.

• 4 external collaborations
• Shared project spending
• Sponsored research fees
• Service charges add cost

General and administrative overhead at 4D Molecular Therapeutics, Inc. covers headquarters, legal, finance, and compliance staff, plus SEC reporting and other public-company duties. These costs fund the corporate backbone, but they also rise with headcount, audits, and disclosure work.

• HQ, legal, finance, compliance
• SEC and audit reporting costs
• Supports corporate infrastructure

Future licensing deals could become a key cash stream for 4D Molecular Therapeutics, Inc. If a program shows strong data, 4D Molecular Therapeutics, Inc. may license it to larger biotech or pharma firms for upfront cash, milestone payments, and royalties. As of the latest filings, 4D Molecular Therapeutics, Inc. still has no product revenue, so this is a likely future monetization path.

• Upfront fee at signing
• Milestones tied to progress
• Royalties on sales

4D Molecular Therapeutics, Inc. is still pre-commercial, so product revenue is 0 today and future sales are only prospective. If its gene therapies win FDA approval and payer access, they could generate direct product sales, but the timing depends on regulatory success and market coverage.

• 0 current product revenue
• Revenue depends on approvals
• Market access is key